-
Professor Tong Wang Analyzes the Clinical Challenges of Multilineage Involvement in BCR::ABL1-Positive B-ALL丨13th Lu Daopei Hematology Conference
PART 1 At both the EHA meeting and this conference, you focused on multilineage-involved BCR::ABL1-positive B-ALL. Could you share the motivation and clinical background for this study? How common are…
-
Professor Jianping Zhang: Optimizing Indication Selection, Timing, and Technical Innovations in Pediatric SAA Transplantation丨13th Lu Daopei Hematolog
PART 1 Your center has accumulated extensive experience with pediatric severe aplastic anemia. Compared with traditional immunosuppressive therapy, what key standards guide your team’s selection of transplant indications? Could you…
-
Professor Daniel Hartson Provides In-depth Analysis of DLBCL’s Genetic Complexity and Innovative Research Models丨EHA 2025
In 2025, the highly anticipated 30th European Hematology Association (EHA) Annual Congress was grandly held in Milan, Italy. This conference brought together top experts and scholars from around the world to discuss cutting-edge topics in basic research and clinical translation in the field of hematolog.Professor Daniel Hartson from the University of Cambridge delivered an insightful…
-
Professor Xian Zhang: Follow-Up Data on ALL Patients Who Did Not Undergo Transplantation After CAR-T Therapy丨13th Lu Daopei Hematology Conference
PART 1 In ALL patients achieving deep remission after CAR-T therapy, are there clear clinical or biological features that help identify those most suitable for a non-transplant approach? How do…
-
Conquering Multiple Myeloma: Professor Jesús San Miguel Shares 45 Years of Research Excellence and the Five Pillars on the Path to a Cure| EHA 2025
The 2025 European Hematology Association (EHA) Annual Congress was grandly convened in Milan, Italy, bringing together the world’s top hematology experts for an academic feast. At this congress, Professor Jesús San Miguel of the University of Navarra Clinic in Spain was honored with EHA Lifetime Achievement Award for his revolutionary contributions to the field of…
-
Professor Rakesh Popat Elaborates on the Phase I Study Results of the Novel BCMA/GPRC5D/CD3 Trispecific Antibody丨EHA 2025
In 2025, the 30th Annual Congress of the European Hematology Association (EHA) was held in Milan, Italy. As a premier event in the global hematology field, this year’s congress attracted thousands of experts and scholars from around the world, with nearly 4,000 abstracts submitted. Among the many studies, a Phase I clinical trial of the…
-
Key Findings of the Phase III POLARGO Study Highlight Pola-R-GEMOX as a Potential New Standard of Care for Transplant-Ineligible Patients丨EHA 2025
Diffuse Large B-cell Lymphoma (DLBCL) is the most common subtype of aggressive non-Hodgkin lymphoma in adults. For patients who are relapsed or refractory after first-line therapy and are not candidates…
-
SURPASS-ET Study Results Released: Ropeginterferon as Second-Line Therapy for High-Risk ET Achieves Dual Breakthrough in Efficacy and Safety丨EHA 2025
At the recently held International Congress of Hematology, treatment advances in the field of Myeloproliferative Neoplasms (MPN) have garnered significant attention. As a classic subtype of MPN, Essential Thrombocythemia (ET) has seen no substantial breakthroughs in its treatment over the past two decades. In a Plenary Presentation, Professor Harry Gill of the University of Hong…
Connecting Medical Expertise through Media